| Metric | Q2'26 | Q3'26 | Change |
|---|---|---|---|
| Revenue | $4.7B, +2.6% YoY | $5.0B, +4.4% YoY | +$300M (+6.4% absolute) increase |
| Adjusted EPS | $2.90, +3.9% YoY | $3.23, +4.9% YoY | +$0.33 (+11.4% YoY) increase |
| Adjusted Operating Margin | 24.2% | 24.9% | +70 bps |
| Adjusted Gross Margin | 54.7% | 54.3% | -40 bps |
| Free Cash Flow (YTD) | $1.1B | $1.7B, +45% YoY | +$600M (+54% YoY) |
| Net Leverage | 2.9x | 2.9x | Flat |
| Biopharma Systems Revenue | -1.8% YoY | +5.2% YoY | Turnaround to double‑digit growth |
| Connected Care Revenue Growth | 12% YoY in APM segment | Double‑digit growth in advanced patient monitoring | Accelerated growth |
| Specimen Management Growth | U.S. growth highlighted in Q2 | High single‑digit growth driven by share gains | Consistent |
| Alaris Headwind | 100 bps headwind in FY26 | 200 bps headwind into FY27 | Doubling of drag |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.